INTRODUCTION
The vascular endothelium lies at a critical tissue interface and is capable of mounting specific responses to a variety of soluble and physical factors. A healthy vascular endothelium is required to sustain blood flow, maintain an anti-coagulant surface, regulate vascular permeability and to minimize inappropriate leucocyte adhesion. Endothelial dysfunction, which is characterized by impaired NO (nitric oxide) synthesis, is a recognized feature of diabetes mellitus, renal failure and systemic inflammatory diseases, and predisposes to accelerated atherogenesis, myocardial infarction and stroke [1] . Thus, given the importance of vascular endothelial injury, apoptosis and inflammation in the initiation and progress of atherosclerosis [2] , understanding the molecular mechanisms regulating EC (endothelial cell) cytoprotective gene expression is critical for the development of novel disease-modifying and preventative therapies.
PKC (protein kinase C) is a phospholipid-dependent serine/ threonine kinase family divided into three subgroups on the basis of their structure and dependence upon specific cofactors for activation. The conventional or classical isoforms include α, βI, βII and γ , the novel isoforms include δ, ε, θ and η/L, and the atypical isoforms include λ/ι and ζ . Negatively charged phospholipids are needed for the activation of all isoforms. The novel isoforms require DAG (diacylglycerol), the conventional isotypes are optimally activated by the additional binding of calcium, whereas atypical PKCs are unresponsive to either calcium or DAG [3] . Individual PKC isoforms exert cell-type and stimulus-specific effects, a concept well illustrated by the opposing effects of PKCδ and PKCε during ischaemia/ reperfusion [4] . PKCε promotes cell survival, and functions as an oncogene in malignancies, including prostate and breast carcinomas [5, 6] . In line with these pro-survival properties is the cytoprotective anti-apoptotic role played by PKCε during cardiomyocyte ischaemic preconditioning [7, 8] . This response in cardiomyocytes involves downstream modulation of the MAPKs (mitogen-activated protein kinases) ERK1/2 (extracellular-signal-regulated kinase 1/2) and JNK (c-Jun
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N-terminal kinase) [9] [10] [11] , and the increased binding activity of AP-1 (activator protein-1) and NF-κB (nuclear factor κB) [12] . In contrast, although vasculoprotective stimuli such as VEGF (vascular endothelial growth factor) A and laminar shear stress may induce PKCε phosphorylation, relatively little is known about PKCε signalling in the vascular endothelium [13] [14] [15] [16] [17] . The NF-κB family of transcription factors contains five proteins that combine to form a variety of hetero-and homo-dimers including p50/p65, which is the most abundant form of NF-κB in ECs [18] . Following EC activation by TNFα (tumour necrosis factor α), NF-κB drives transcription of pro-inflammatory transcripts, including the cellular adhesion molecules E-selectin, VCAM-1 (vascular cell adhesion molecule 1), ICAM-1 (intercellular adhesion molecule 1) and the chemokine IL-8 (interleukin-8). However, equally important is the induction of NF-κB-dependent anti-inflammatory and cytoprotective genes such as manganese superoxide dismutase, A1, A20, Bcl-2 and GADD45β (growth-arrest and DNA-damage-inducible protein 45β), that serve to terminate the pro-inflammatory response and protect the endothelium against apoptosis [19] [20] [21] [22] .
We previously demonstrated that treatment with VEGF leads to a physical interaction between PKCε and Akt in human ECs, resulting in enhanced protection against apoptosis [23] . However, whether PKCε plays a more central role in the maintenance of endothelial homoeostasis remains to be determined. In the present study we show that PKCε plays an important role as an upstream regulator of endothelial cytoprotection through both the specific induction of protective genes, as well as suppression of pro-inflammatory responses.
MATERIAL AND METHODS

Reagents
The antibodies used were anti-A20 (Stressgen), anti-Bcl-2 and anti-IκBα (inhibitor of NF-κBα) (Santa Cruz Biotechnology), anti-phospho-PKCε(Ser 729 ) (Upstate Biotechnology), and anti-phospho-ERK1/2(Thr 202 /Tyr 204 ) and anti-phospho-JNK(Thr 183 /Tyr 185 ) (Cell Signaling Technology). The NF-κB inhibitor BAY 11-7085 was from Sigma-Aldrich, the MEK1 (MAPK/ERK kinase 1) inhibitor U0126 was from Merck Biosciences and TNFα was from R&D Systems.
Cell culture
HUVECs (human umbilical vein ECs) were isolated and cultured as described previously [24] . The use of human ECs was approved by Hammersmith Hospitals Research Ethics Committee (reference number 06/Q0406/21). To generate matched wild-type and PKCε − / − EC lines, PKCε-deficient mice [25] (a gift from Professor Peter Parker, Kings College London, London, U.K.) backcrossed on to a C57BL/6 background were crossed with H-2K b -tsA58 transgenic mice and the offspring crossed to generate H-2K b -tsA58/PKCε − / − mice. Cardiac ECs were obtained from these mice and their PKCε + / + littermate controls using enzymatic digestion of hearts and positive selection with anti-endoglincoated microbeads. Their EC phenotype was confirmed as described previously [26] . All mice were studied according to UK Home Office guidelines and with ethical approval from Imperial College London.
Adenoviral infection
Generation and use of the adenoviral vectors expressing CA (constitutively active) and DN (dominant-negative) PKCε, βGal (β-galactosidase), Ad0 (control adenovirus) and IκBα-SR (IκBα SuperRepressor; a gift from Dr Claudia Monaco, Imperial College London, London, U.K.) have been described previously [23, [27] [28] [29] . Adenoviruses were amplified in HEK (human embryonic kidney)-293A cells, purified and titrated [30] . HUVECs were infected by incubation with adenovirus in serum-free M199 for 2 h at 37
• C. The medium was replaced with M199 containing 10 % FBS (fetal bovine serum) and 7.5 μg/ml EC growth factor (Sigma). At that point, U0126 (10 μM), BAY 11-7085 (5 μM) or VEGF (25 ng/ml) was added in some experiments and remained throughout. Optimal MOI (multiplicity of infection) for each adenovirus, expressed as ifu (infectious units) per cell, was determined by Western blot analysis.
siRNA (small interfering RNA) transfection
Pre-validated siRNA duplexes for PKCε (Hs_PRKCE_5 and Hs_PRKCE_6, catalogue numbers SI00287784 and SI02622088 respectively), were purchased from Qiagen. The siRNA for A20 (sense, 5 -GCCCUCAUCGACAGAAACA.dt.dt-3 and antisense, 3 -dt.dt.CGGGAGUAGCUGUCUUUGU-5 ) [31] and negative control sequences were synthesized by Dharmacon. GeneFECTOR (3:50) (VennNova) and siRNA (20 nmol/l final concentration) were diluted separately in Opti-MEM I (Invitrogen). Equal volumes of siRNA and GeneFECTOR solutions were mixed and incubated at room temperature (21
• C) for 5 min. HUVECs were washed and Opti-MEM I medium was added. Transfection solutions were diluted 1:5 into the cultures. After incubation for 4 h, the medium was replaced with EGM2 complete medium (Lonza) and knockdown was assessed at 48 h.
Flow cytometry
Flow cytometry was performed as described previously in detail [24] . Results are expressed as the relative fluorescent intensity, representing MFI (mean fluorescent intensity) with test monoclonal antibody divided by the MFI using the secondary antibody alone.
Quantitative real-time PCR
RNA was extracted using the RNeasy kit (Qiagen). Quantitative RT (reverse transcription)-PCR was carried out using an iCycler (Bio-Rad Laboratories). DNase-1-digested total RNA (1 μg) was reverse-transcribed using 1 μM oligo(dT) and Superscript reverse transcriptase (Invitrogen). cDNA was amplified in a 25 μl reaction mixture containing 5 μl of cDNA template diluted 1:30, 12.5 μl of SYBR supermix (Bio-Rad Laboratories), 5 pmol of each sense and antisense gene-specific primer, and water to adjust the volume. The primer sequences used are shown in Supplementary Table S1 (at http://www.BiochemJ.org/bj/447/bj4470193add.htm). The cycling parameters were 3 min at 95
• C, followed by 40 cycles of 60
• C for 45 s, 95
• C for 60 s, and 60
• C for 60 s.
Western blot analysis
Immunoblotting was performed as described previously [30] . with a chemiluminescence substrate (GE Healthcare). To ensure equivalent sample loading, membranes were re-probed with an anti-tubulin or anti-β-actin antibody. Integrated densities were quantified using ImageJ software (NIH).
NF-κB p50 and p65 activation assay
A TransAM NF-κB ELISA kit (Active Motif) was used according to the manufacturer's instructions to determine the transcriptional activation of NF-κB p50 and p65 subunits. In total, 10 μg of EC nuclear extract was added to each well of a 96-well plate pre-coated with NF-κB consensus binding oligonucleotide (5 -GGGACTTTCC-3 ) and incubated for 1 h at room temperature. After washing, the primary antibody diluted 1:1000 was applied for 1 h at room temperature. Specific binding was estimated by spectrophotometry at 450 nm after incubation with a horseradishperoxidase-conjugated antibody.
Luciferase activity assays
HUVECs seeded at a density of 3×10 4 cells per well in 24-well plates were transfected with CA-PKCε adenovirus or βGal adenovirus and the following day co-transfected with 250 ng of Renilla-luciferase plasmid (internal control), and either a p65 NF-κB-luciferase reporter plasmid or pGL2-luciferase empty plasmid. Cell extract (20 μl) was assayed for luciferase activity using the Dual-Luciferase Assay kit (Promega). The relative level of reporter gene expression was expressed as the ratio of firefly luciferase activity to Renilla luciferase, normalized against the empty plasmid pGL2.
Cell survival assay
Analysis of EC survival was performed using the Promega CellTiter96 MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay according to the manufacturer's instructions. The assay was quantified by recording absorbance (490 nm) using a 96-well ELISA plate reader (Dynex Technologies). The percentage cell death was calculated as follows:
where control represents ECs cultured in M199/20 % FBS alone for the duration of the experiment [23] .
Statistical analysis
Data were expressed as the mean of the individual experiments + − S.E.M. Data were grouped according to treatment and analysed using ANOVA with a Bonferroni multiple comparison test or a paired Students t test (GraphPad Prism 4.0 software). P < 0.05 was considered statistically significant.
RESULTS
PKCε inhibition reduces protective gene expression
To investigate the hypothesis that PKCε is a key regulator of cytoprotective genes in ECs, we initially adopted a loss-offunction approach and analysed constitutive expression of the anti-apoptotic genes Bcl-2 and A1, and the anti-inflammatory gene A20. Initial experiments in cardiac ECs derived from wild-type and PKCε-deficient mice revealed significant reduction of basal Bcl-2 protein in the latter ( Figure 1A ). This led us to studies in human ECs using RNAi (RNA interference) targeting of PKCε (Supplementary Figure S1A at http://www.BiochemJ.org/bj/447/bj4470193add.htm). Depletion of PKCε in HUVECs also led to significant reduction in basal Bcl-2 transcript and protein expression ( Figures 1B and 1C) . Likewise, depletion of PKCε resulted in a marked reduction in both A20 and A1 transcripts ( Figures 1D and 1E ).
A1 expression is up-regulated by VEGF [32] and this response was used to investigate the physiological regulatory role of PKCε in cytoprotective signalling. First, using a previously validated adenoviral vector [29, 30] , expression of DN-PKCε was shown to reduce basal A1 expression, a response not seen with the βGal control adenovirus ( Figure 1F ). Exposure of ECs to VEGF for 7 h increased A1 mRNA levels and this response was significantly attenuated by DN-PKCε ( Figure 1G) . Furthermore, the up-regulation of EC Bcl-2 protein following 16 h of VEGF treatment was also attenuated by siRNA-mediated depletion of PKCε (Supplementary Figure S1B) . Taken together, these results suggest that PKCε plays an important homoeostatic role in vascular ECs by contributing to both basal and VEGF-induced expression of cytoprotective genes.
PKCε activation induces EC anti-apoptotic and anti-inflammatory genes
To demonstrate a direct link between PKCε activity and cytoprotective gene expression, we made use of a well-characterized adenoviral vector (CA-PKCε adenovirus) expressing PKCε rendered CA by the deletion of residues 154-163 in the inhibitory pseudosubstrate domain [23, 28] . Transfection of HUVECs with CA-PKCε adenovirus led to a dose-dependent increase in PKCε(Ser 729 ) phosphorylation, optimal at an MOI of 50-200 ifu/cell (Supplementary Figure  S1C) . Expression of activated PKCε (MOI of 50) resulted in a parallel increase above controls of Bcl-2 (3.29 + − 0.4), A20 (8.08 + − 1.72) and A1 (8.09 + − 1.73) mRNA levels, which were maximal 16 h post-transfection and not seen in βGal control adenovirus or mock-transfected cells (Figure 2 ).
The cytoprotective role of PKCε is MEK1/2-ERK1/2-dependent
In light of its role in cell survival, we sought to establish a relationship between the MEK1/2-ERK1/2 MAPK pathway and PKCε. When compared with mock-transfected or βGal-transfected cells, ECs transfected with CA-PKCε showed a significant increase in ERK1/2(Thr 202 /Tyr 204 ) phosphorylation ( Figure 3A) . Immunoblotting revealed induction of both A20 and Bcl-2 protein 24 h after PKCε activation, a response that was inhibited by the MEK1/2 antagonist U0126 ( Figure 3B ). The absence of a suitable immunoblotting antibody precluded the study of A1 protein. However, the increase in A1 transcripts seen following PKCε activation was also inhibited by U0126 ( Figure 3C ). These results suggest that activation of the MEK1/2-ERK1/2 pathway is an important downstream component of the cytoprotective response driven by PKCε. In contrast with the cell survival function of ERK1/2 signalling in the vascular endothelium, phosphorylation of JNK has been linked to pro-apoptotic and pro-inflammatory effects [1] . Moreover, as functional cross-talk between MAPK pathways in the endothelium has been reported [33] , we investigated the hypothesis that PKCε-induced ERK1/2 phosphorylation might inhibit JNK1/2 activation. In ECs pre-transfected with the βGal control adenovirus, the pro-inflammatory cytokine TNFα induced JNK1/2(Thr 183 /Tyr 185 ) phosphorylation, a response that was significantly inhibited in cells expressing CA-PKCε (Figure 4) . However, as shown in Figure 4 , the ability of PKCε to inhibit JNK1/2 phosphorylation was not altered by U0126, suggesting that the response is independent of ERK1/2.
PKCε-mediated induction of NF-κB is cytoprotective
NF-κB may regulate cytoprotective gene expression in ECs and has previously been identified as a transcriptional target of PKCε [12] . To investigate the role for NF-κB downstream of PKCε in ECs, cells were co-transfected with CA-PKCε adenovirus and an NF-κB p65 luciferase reporter or the pGL2 empty vector. As shown in Figure 5 (A), NF-κB p65 promoter activity was increased in HUVECs overexpressing PKCε when compared with βGal-transfected control ECs. A DNA-binding ELISA further demonstrated increased NF-κB p65 activation in nuclear extracts of PKCε-transfected ECs, a response not seen in control-transfected cells ( Figure 5B ). Quantification of PKCε-induced changes in p65 NF-κB binding activity in the presence and absence of the MEK1/2 inhibitor U0126 showed that this response was unaffected by inhibition of MEK1/2-ERK1/2 ( Figure 5B ). Thus the results of the present study suggest that PKCε-mediated cytoprotective gene induction involves MEK1/2-ERK1/2 and NF-κB signalling pathways acting in parallel.
To demonstrate a role for NF-κB in cytoprotective gene induction, we adopted a pharmacological and molecular approach using BAY 11-7085, an inhibitor of IκBα phosphorylation, and an IκBα-SR adenovirus expressing mutated IκBα resistant to phosphorylation and degradation. IκBα-SR was used at the optimal MOI of 100 ifu/cell, determined by the inhibition of TNFα-induced E-selectin expression (Supplementary Figure  S2 at http://www.BiochemJ.org/bj/447/bj4470193add.htm). The IκBα-SR attenuated PKCε-dependent induction of A1, A20 and Bcl2 mRNA transcripts when compared with the βGal control virus. The role of NF-κB in this response was further supported by the significant fall in PKCε-induced Bcl-2 and A20 protein levels seen in the presence of BAY 11-7085 or IκBα-SR ( Figure 6B ). These results demonstrate a central role for increased NF-κB activity in the induction of cytoprotective genes by PKCε.
Next, a serum-starvation assay was used to explore the functional role of ERK1/2 and NF-κB signalling in PKCε-regulated cytoprotection. As shown in Figures 6(C) and 6(D) , serum-starvation (M199/0.1 % FBS for 24 h) led to 40 % cell death. Expression of CA-PKCε significantly reduced cell cytotoxicity, a response not seen in ECs transfected with a control virus. The protective response was abrogated by treatment of ECs with either U0126 or BAY 11-7085, demonstrating the importance of ERK1/2 and NF-κB pathways in the cytoprotective actions of PKCε.
PKCε activity fails to induce pro-inflammatory cell adhesion molecules
Activation of NF-κB in ECs is most closely associated with the expression of pro-inflammatory genes, and to explore the effect of PKCε activation in this setting, we quantified cellsurface expression of E-selectin, VCAM-1 and ICAM-1 by flow cytometry. In contrast with the cytoprotective genes, PKCε activation failed to increase expression of either E-selectin or VCAM-1 above that seen with the βGal adenovirus. Although a small increase in ICAM-1 was seen (βGal, 1.0 + − 0.03 compared with CA-PKCε, 1.41 + − 0.2) (Figure 7) , this was insignificant when compared with TNFα treatment for 6 h, which led to a 12-fold induction of ICAM-1 ( Figure 7C ), and also up-regulated Eselectin (35-fold) (Supplementary Figure S2) and VCAM-1 (10-fold) (results not shown). Thus these data suggest that activation of NF-κB downstream of PKCε specifically induces protective genes.
PKCε inhibits TNFα-induced ICAM-1 expression via induction of A20
To explore the anti-inflammatory effects of PKCε activation, we focused on A20 and adopted a loss-of-function approach using validated A20 siRNA [31] , which depleted protein expression in HUVECs by up to 80 % ( Figure 8A ). Resting HUVEC monolayers, mock-transfected cells and those transfected with control siRNA, either alone or in association with βGal adenovirus, demonstrated no significant change in ICAM-1 expression ( Figure 8B ). Co-transfection of CA-PKCε and control siRNA resulted in a small induction of ICAM-1, equivalent to that seen with CA-PKCε in Figure 7 (C). Following depletion of A20 in resting ECs, the expression of ICAM-1 was increased 3-4-fold. Furthermore, an additional significant increase in ICAM-1 protein was seen in A20-deficient ECs also expressing CA-PKCε, suggesting that induction of A20 plays an important role in suppressing pro-inflammatory genes following activation of NF-κB by PKCε. Next, TNFα-mediated induction of ICAM-1 was used as a model inflammatory response. The inhibition of TNFα-induced JNK phosphorylation by CA-PKCε shown in Figure 4 suggested that the latter would inhibit pro-inflammatory effects of TNFα. ICAM-1 was up-regulated on the surface of mocktransfected and control-adenovirus-transfected ECs exposed to TNFα ( Figure 9A) . Expression of CA-PKCε (MOI of 50-500) RNAi was used to explore the role of A20 in the PKCε-mediated inhibition of ICAM-1 up-regulation. As seen in Figures 9(D) and 9(E), PKCε significantly attenuated TNFα-induced ICAM-1, whereas depletion of A20 enhanced ICAM-1 up-regulation by TNFα in mock-transfected and βGal-adenovirus-transfected ECs. Furthermore, depletion of A20 inhibited the protective effect of PKCε, with ICAM-1 levels rising from 1.92 + − 0.53 to 4.99 + − 1.61. However, siRNA depletion of A20 did not completely attenuate the anti-inflammatory effect of PKCε, as some reduction in ICAM-1 expression remained when compared with either knockdown of A20 alone or with βGal-transfected ECs ( Figure 9D ). This may reflect the inability of siRNA to completely deplete A20, or perhaps more likely the involvement of other PKCε-inducible anti-inflammatory genes. Overall, the results of the present study reveal the diverse anti-inflammatory and cytoprotective actions of PKCε, and suggest that it plays a central role in protection against vascular injury and endothelial dysfunction.
DISCUSSION
We have shown that PKCε regulates constitutive expression of the EC cytoprotective genes A1, A20 and Bcl-2, and that specific enhanced activation of PKCε drives expression of these genes via an ERK1/2-and NF-κB-dependent pathway. The physiological relevance of PKCε for endothelial homoeostasis was revealed by its role in VEGF-induced up-regulation of A1 and Bcl-2. Importantly, although up-regulating protective genes, PKCε-mediated activation of NF-κB failed to induce NF-κB-regulated pro-inflammatory targets E-selectin, VCAM-1 and ICAM-1. Moreover, the protective role of PKCε was further demonstrated by its ability to inhibit TNFα-induced JNK phosphorylation and ICAM-1 up-regulation, with the latter, at least in part, reflecting a PKCε-dependent increase in A20. These data reveal a central role for the PKCε-ERK1/2-NF-κB signalling pathway in the maintenance of endothelial homoeostasis, through its ability to specifically regulate both anti-inflammatory and anti-apoptotic genes. Vascular endothelial injury is the earliest detectable event in atherogenesis, with the disruption of homoeostatic functions and reduced NO biosynthesis followed by low-grade chronic inflammation, endothelial dysfunction and structural lesions [1, 2] . Although the serine/threonine kinase PKCε is recognized to play a critical role in ischaemic preconditioning of cardiomyocytes [7, 8, 34] , its function within the vascular endothelium remains poorly defined. However, a cytoprotective role is emerging. PKCε is involved in ERK1/2 phosphorylation induced by laminar shear stress, and in the regulation of eNOS (endothelial NO synthase) and ERK1/2 activity by VEGF [13, 16] . PKCε activation protects ECs against oxidative stress [35] and we have previously reported its role in VEGF-dependent EC resistance to apoptosis and complement-mediated injury [23, 30] . We have shown in the present study that PKCε selectively induces A1 and Bcl-2 without altering expression of other anti-apoptotic genes such as GADD45β or Bcl-xl (results not shown). A1 is an anti-apoptotic Bcl-2 family member that acts within mitochondria to maintain membrane stability and reduce cytochrome c-mediated caspase 9 activation [36] . A role for PKC in A1 regulation was first shown using the broad-spectrum antagonists calphostin C and H7 [37] , and we have now identified PKCε as the isoform responsible. Furthermore, we have identified an important anti-inflammatory role for PKCε in ECs, mediated, at least in part, via induction of A20, a zinc-finger protein known for its role in the resolution of the inflammatory response triggered by TNFα [19] .
To explore the role of signalling pathways downstream of PKCε we initially investigated ERK1/2, a MAPK which promotes EC survival and is activated by PKCε in cardiomyocytes [28] . Our findings in HUVECs show an increase in ERK1/2 phosphorylation following PKCε overexpression, and are in agreement with those reported in bovine aortic ECs in which inhibition of PKCε prevented shear-stress-induced ERK1/2 activation [13] . In addition, we have demonstrated that MEK1/2-ERK1/2 inhibition suppresses PKCε-mediated induction of cytoprotective target genes A1, A20 and Bcl-2. In contrast, JNK is reported to mediate pro-inflammatory responses elicited by TNFα, and is closely associated with endothelial apoptosis [1] . We have now shown that PKCε activation abrogates TNFα-dependent JNK1/2 phosphorylation. Of note, similar protection against apoptosis is conferred by the PKCη isoform in the human breast cancer cell line MCF-7 [38] . On the other hand, several groups have demonstrated PKCε-induced JNK1/2 activation in cardiomyocytes [12, 28] , further reinforcing the cell-type-specificity of individual PKC isoforms. The results of the present study suggest that PKCε utilizes a dual mechanism to exert its cytoprotective effects in ECs by activating the MEK1/2-ERK1/2 pathway, and additionally inhibiting TNFα-driven JNK phosphorylation. Since inhibitory cross-talk between ERK1/2 and JNK has been reported [33] , we reasoned that inhibition of JNK phosphorylation by PKCε might be attributable to ERK1/2. However, ERK1/2 inhibition failed to re-establish JNK activation by TNFα, implying that PKCε inhibits JNK independently of ERK1/2.
The transcription factor NF-κB may regulate both proinflammatory and pro-survival responses, with the latter including the induction of Bcl-2, A1 and A20. The loss of A1, A20 and Bcl-2 up-regulation when NF-κB was inhibited by the IκB-SR or BAY 11-7085, reveals a central role for NF-κB in PKCε-dependent induction of these cytoprotective genes. Moreover, the contribution of NF-κB was reinforced by the demonstration that PKCε drives NF-κB promoter activity. However, in contrast with the cytoprotective genes, the pro-inflammatory NF-κB targets E-selectin and VCAM-1 were not up-regulated by PKCε-mediated NF-κB activation, whereas only a very modest increase in ICAM-1 was seen. We have reported similar endothelial responses to shear stress, which can alter NF-κB function by simultaneously suppressing pro-inflammatory and enhancing anti-apoptotic gene activation [39] . The functional relevance of PKCε-induced activation of ERK1/2 and NF-κB signalling pathways was revealed using a serum-starvation cell survival assay, in which the protection afforded by enhanced PKCε activity against cytotoxicity was lost if either downstream signalling pathway was inhibited. The precise molecular mechanisms through which NF-κB controls protective compared with pro-inflammatory gene expression in response to various stimuli remain to be fully defined, with a number of potential pathways under investigation. First, differential binding of NF-κB to specific target gene promoters might be explained by a difference in binding affinity between NF-κB-response elements [40] . Likewise, a role for post-translational modification can be envisaged [41] . Indeed, epigenetic mechanisms, such as the recruitment of specific co-activators and co-repressors to individual promoters and associated changes in histone acetylation and deacetylation, has been suggested as a mechanism likely to play an important role in NF-κB-driven gene expression patterns [42, 43] . Similarly, phosphorylation of specific residues may elicit transcription of a particular gene. Thus p65 subunit phosphorylation on Ser 535 [44] and Ser 536 [45] has been reported to lead to the inhibition of apoptosis in HeLa cells and myofibroblasts. One or more of these mechanisms may be involved in the selectivity of PKCε-induced NF-κB activation in ECs and, although beyond the scope of the present study, this is the subject of on-going research.
The observed up-regulation of A20, along with the failure to induce cell adhesion molecules, led us to explore in more detail the anti-inflammatory actions of PKCε. The results of the present study show that PKCε activity is able to attenuate TNFα-induced ICAM-1 up-regulation. Moreover, the protection afforded by PKCε was, at least in part, dependent upon its induction of A20, as specific depletion of A20 resulted in a rebound in ICAM-1 expression. Thus, by increasing A20, PKCε may amplify the negative-feedback loop for the regulation of NF-κB. However, activation of PKCε did not prevent the initial degradation of IκBα by TNFα. Therefore we propose that, in addition to the induction of A20, PKCε acts to inhibit TNFα-activated JNK/AP-1 signalling and so further represses ICAM-1 up-regulation. In support of this, we found that transfection of ECs with CA-PKCε inhibited TNFα-induced JNK phosphorylation. PKC activity has previously been shown to down-regulate JNK/AP-1 in hepatocytes [46] , and PKCε itself is reported to activate protein kinase D, which in turn inhibits JNK activation in HEK cells [47] .
Furthermore, a recent study suggests that, in addition to its antiinflammatory role, A20 exerts anti-apoptotic effects by promoting ASK1 (apoptosis signal-regulating kinase 1) degradation and subsequent suppression of JNK activation [48] .
In conclusion, the present study demonstrates that, in primary human ECs, activation of PKCε exerts combined anti-apoptotic and anti-inflammatory effects by: (i) selectively orientating the NF-κB pathway towards induction of the cytoprotective genes A1, A20 and Bcl-2, and (ii) activating a protective MEK1/2-ERK1/2 pathway and inhibiting JNK1/2 phosphorylation. Thus we propose that PKCε represents both an essential component of vascular endothelial homoeostasis and a potential therapeutic target.
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Primer name Sequence
Actin forward 5 -GAGCTACGAGCTGCCTGACG-3 Actin reverse 5 -GTAGTTTCGTGGATGCCACAGGACT-3 A1 forward 5 -CACAGGAGAATGGATAAGGCAAA-3 A1 reverse 5 -AGTCATCCAGCCAGATTTAGGTTC-3 A20 forward 5 -CACACAAGGCACTTGGATC-3 A20 reverse 5 -CTGTAGTCCTTTTGAAGCAAGT-3 Bcl-2 forward 5 -GTCATGTGTGTGGAGAGCGT-3 Bcl-2 reverse 5 -GCCGTACAGTTCCACAAAGG-3 GADD45β forward 5 -GTCGGCCAAGTTGATGAATGT-3 GADD45β reverse 5 -GGATTTGCAGGGCGATGT-3
